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Abstract
Inflammation is the result of a complex network of cellular and
molecular interactions and mechanisms that facilitate immune
protection against intrinsic and extrinsic stimuli, particularly
pathogens, to maintain homeostasis and promote tissue healing.
However, dysregulation in the immune system elicits excess/
abnormal inflammation resulting in unintended tissue damage
and causes major inflammatory diseases including asthma, chronic
obstructive pulmonary disease, atherosclerosis, inflammatory
bowel diseases, sarcoidosis and rheumatoid arthritis. It is now
widely accepted that both endoplasmic reticulum (ER) stress and
inflammasomes play critical roles in activating inflammatory
signalling cascades. Notably, evidence is mounting for the
involvement of ER stress in exacerbating inflammasome-induced
inflammatory cascades, which may provide a new axis for
therapeutic targeting in a range of inflammatory disorders. Here,
we comprehensively review the roles, mechanisms and interactions
of both ER stress and inflammasomes, as well as their
interconnected relationships in inflammatory signalling cascades.
We also discuss novel therapeutic strategies that are being
developed to treat ER stress- and inflammasome-related
inflammatory disorders.
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INTRODUCTION
Humans are constantly exposed to a myriad of
potentially harmful exogenous stimuli, particularly
opportunistic and pathogenic microorganisms,
environmental allergens and noxious particles and
irritants. To defend against these challenges,
humans have evolved a fine-tuned and highly
effective immune system comprised of innate and
adaptive immunity.1 The innate immune system
consists of anatomical barriers, the complement
system, inflammatory cascade and immune cells
(e.g. neutrophils, macrophages, eosinophils, mast
cells). It plays an essential role as the frontline of
immune defence in preventing pathogen invasion.
The innate system detects danger signals by
recognising pathogen (PAMPs)- and danger
(DAMPs)-associated molecular patterns.1 PAMPs,
such as bacterial endotoxins and flagellin, are
distinguishable from host factors. DAMPs include
heat shock (HSP) and high-mobility group box
proteins, adenosine triphosphate (ATP), cytosolic
ribonucleic acids (RNAs), and cytosolic and
mitochondrial deoxyribonucleic acids (DNAs) that
are released by damaged or stressed cells. PAMPs
and DAMPs are recognised by membrane-bound
or cytosolic pattern recognition receptors (PRRs),
enabling innate immune cells to discriminate
pathogen and foreign materials from host cells.1
The adaptive immune system is mainly regulated
by T- and B-lymphocytes and provides long-lasting
protection against previously encountered
microbes through the recognition of foreign
antigens.
Inflammation is initiated and regulated by
complex interactions of immune cells that
encounter exogenous stimuli, as well as
endogenous pro-inflammatory cytokines.1,2 These
factors impact the resultant severity, type and
duration of inflammation. Infection with
microbes, either opportunistic or pathogenic, can
exaggerate inflammatory responses, damaging
host cells and leading to acute, chronic, local and
systematic inflammatory disorders. Among
immune system mediators, inflammasomes have
recently attracted global attention as potential
therapeutic targets for treating chronic
inflammatory diseases. Inflammasomes are innate
immune system mediators that induce and
regulate inflammation upon challenge by
pathogens and environmental allergens. They are
linked to a myriad of autoimmune and
inflammatory diseases, including multiple sclerosis,
Alzheimer’s disease, atherosclerosis, diabetes,
inflammatory bowel disease, severe asthma and
chronic obstructive pulmonary disease (COPD).3–10
ENDOPLASMIC RETICULUM (ER)
STRESS
Endoplasmic reticulum stress is a cellular stress
that occurs when the protein folding function of
the ER has reached its maximum capacity leading
to impairment of the folding process.11 In
eukaryotic cells, cytoplasmic ribosomes
continuously synthesise proteins that are required
for daily metabolic activity. Before secretion, these
proteins are transferred to the membrane-bound
ER for further post-translational modification and
quality control.12 The ER is exquisitely sensitive to
intracellular and extracellular stimuli.11 Any
perturbations in the cell, such as pathogen
infection, allergen exposure, redox homeostasis
imbalance and the effects of cytotoxins, can affect
protein biosynthesis and may result in misfolded
proteins with altered functions.11,13 Misfolded
proteins are continuously produced in cells, in
direct proportion to the complexity and amount
of proteins generated.12 For instance, intestinal
goblet cells, which produce significant amounts of
complex mucin (MUC)-2 protein under
physiological conditions, are particularly
susceptible to ER stress.12,14 Due to perturbations
in protein folding processes, irregular functional
proteins are produced, along with misfolded
proteins.13 In order to meet homeostasis demands,
cells upregulate protein biosynthesis processes to
increase the production of required proteins, and
this response simultaneously increases the
formation of misfolded protein, which further
exacerbate misfolded protein aggregation and
reinforce ER stress.
Most misfolded proteins do not exert any
cellular function and pose a burden for cells.
Hence, these proteins need to be re-folded or
removed. Several mechanisms have evolved to
reduce and remove misfolded proteins. The ER is
responsible for protein proofing and ensuring
that all initiated proteins are correctly folded
before secretion out of the cell. Misfolded
proteins are subject to re-folding until they are
successfully folded, whereas terminally misfolded
proteins are retro-translocated into the cytosol for
ER-associated degradation (ERAD) either via the
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ubiquitin-proteasome system or are degraded in a
ubiquitin independent manner.15–17 The ER
contains numerous chaperones that assist the
protein folding process, including HSP60, calnexin,
calreticulin and glucose-regulated protein (GRP)
78.15 These chaperones facilitate the quality
control and post-translational modifications of the
nascent proteins, promote the protein re-folding
process, transfer nascent protein into and out of
the ER, identify and bind to misfolded proteins,
and retro-translocate terminal misfolded protein
into the cytosol for ERAD.15,18 Moreover,
chaperones play vital roles in various molecular
processes, such as peptide cleavage, glycosylation
and disulphide bonding. Overall, chaperones assist
ER activities while maintaining ER homeostasis.
Even with advanced quality control and
turnover of protein production in the ER, altered
physiological and pathological conditions can
compromise ER homeostasis, reduce the efficiency
of protein folding mechanisms and cause
aggregation of misfolded proteins.19 The triggers
for ER dysfunction include inflammation, hypoxia,
nutrient depletion, oxidative stress, redox
imbalance, upregulated protein biosynthesis, and
calcium deficiency.19 This can drive diseases, and
indeed, patients with pathological conditions,
such as infection, neurodegenerative disorders,
metabolic syndrome, and inflammatory diseases,
have perturbations in ER homeostasis.19 Notably,
if the production of misfolded proteins
overwhelms protein re-folding mechanisms in the
ER, misfolded proteins will accumulate in cells.20
Consequently, cells undergo the cellular stress
condition of ER stress. Cells with ER stress exhibit
distinct morphological changes compared to
healthy cells, including ribosome dissociation, ER
luminal swelling and expansion, and atypical ER
structure. Moreover, ER stress has a substantial
impact on overall cellular activities by altering
protein biosynthesis, reducing functional protein
production, and interfering with intracellular and
extracellular signalling cascades,21 and when
chronic can induce apoptosis.21,22 All of these
mechanisms contribute to pathogenesis in various
inflammatory conditions, including inflammatory
bowel disease, atherosclerosis, diabetes, asthma
and COPD.20,23–26
To limit ER stress-induced cellular abnormalities,
cells are equipped with a network of
multifactorial, parallel, and independent
transcriptional and signalling pathways,
collectively known as the unfolded protein
response (UPR).27 The major role of the UPR is to
increase ER folding capacity, re-fold marginally
misfolded proteins, and remove terminally
misfolded proteins. The UPR consists of numerous
cellular pathways that promote the ER protein
folding process, reduce overall protein
biosynthesis, and activate ERAD to eliminate
aggregated misfolded proteins in the ER.27 The
UPR can also trigger apoptotic cascades if the
stress condition overwhelms its’ capacity.27 In the
UPR process, the chaperone GRP78 has a pivotal
role in controlling protein synthesis, folding and
assembly. This chaperone is a sensor of misfolded
proteins, and initiates the UPR signalling
cascade.27 Under normal conditions, GRP78 is
attached to and inhibits three ER-localised
transmembrane UPR signal transducers, including
inositol-requiring kinase (IRE)1, activating
transcription factor (ATF)6, and protein kinase
RNA-like ER Kinase (PERK).28 However, in ER
stress, misfolded proteins are produced and
aggregate in the ER, where they are sensed by
GRP78.28 As a result, UPR signal transducers are
released by GRP78, and bind to misfolded
proteins within the ER. This activates the UPR
signal transducers and downstream signalling
cascades.11 These transducers collaborate to
promote protein folding mechanisms and
eliminate misfolded proteins. This is the
traditional view of how the ER recognises
misfolded proteins. However, several reports show
that misfolded proteins can directly bind to IRE1
or PERK to initiate the UPR.29,30 Although the UPR
is a cytoprotective process, it can be cytotoxic
during severe and persistent ER stress.31 It is
notable that ER stress is not exclusively a
pathological condition as healthy cells undergo
this while secreting large amounts of proteins.
The IRE1–X-box binding protein (XBP1) signalling
pathway is induced during the differentiation of
B cells to plasma cells, and in the development
and survival of conventional and plasmacytoid
dendritic cells.32–35 Thus, the UPR is involved in
proteostasis and in fine-tuning the protein
synthesis process during normal cellular functions,
but can become dysfunctional and contribute to
the pathogenesis of disease.
IRE1
The IRE1 signalling cascade is the most conserved
UPR signalling mechanism, and is present in all
eukaryotes.36 IRE1 is a type 1 transmembrane
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sensor protein, which has an amino-terminal ER
luminal domain, a single-pass transmembrane
segment, and a carboxyl-terminal cytoplasmic
kinase and RNase domain.37 In mammalian cells,
there are two IRE1 isoforms, IRE1a and IRE1b.38
IRE1a is ubiquitously expressed in all mammalian
cells that have an ER, whereas IRE1b is only found
in lung and gut-derived cells.38 Under
physiological conditions, IRE1 is constitutively
bound to GRP78. During ER stress, GRP78 releases
IRE1, allowing it to undergo activation and
oligomerisation.38 IRE1 has a kinase domain that
can be autophosphorylated as part of its
activation process.39 This triggers its RNA
endonuclease activity, which is crucial for the
downstream signalling cascade.39 Oligomerisation
of IRE1 has been visualised microscopically as foci
in vivo and is required for downstream
signalling.18,40 Importantly, autophosphorylation
of IRE1 does not trigger downstream signalling by
initiating a phosphorylation cascade, but instead
signalling occurs as a result of oligomerisation
and activation of the nucleotide-binding site of
the IRE1 RNase domain.41 Once activated, IRE1
selectively excises a messenger (m)RNA that
encodes the transcription factor XBP1. This process
occurs through precise cleavage either side of a 22
nucleotide intron, and the remaining mRNA is re-
joined by RtcB ligase.39 The excision causes a
frameshift in the XBP1 translational sequence and
produces the functional protein, spliced XBP1
(XBP1s). Activated XBP1 contains a basic leucine
zipper domain (bZIP) that promotes the
expression of target genes, which encode ER
chaperones and ERAD components to increase
protein folding and ERAD capacity.
PERK
Similar to IRE1, PERK is also a type 1
transmembrane protein. It has an ER luminal
domain and a cytosolic kinase domain that is
structurally and functionally identical to IRE1, and
undergoes autophosphorylation during ER stress.42
Although it has a similar activation pattern,
activated PERK recruits and phosphorylates a
different transcription factor, eukaryotic initiator
factor (EIF)2a.42 EIF2a is critical in protein
biosynthesis, as it promotes the binding of initiator
transport RNA (tRNA) to 40S ribosomal subunits, as
well as forming a ternary complex with guanosine
triphosphate and methionyl tRNA, which are vital
in the early stages of protein synthesis.43
EIF2a phosphorylation can inhibit general
protein synthesis and thereby reduce the demand
for protein folding processes and relieve the
burden on the ER. EIF2a phosphorylation also
simultaneously initiates another protein
translation process that is exclusive for ER-resident
proteins. It allows the translation of mRNA that
contain inhibitory upstream open reading frames
in their untranslated regions, which do not
translate under normal conditions.44 As a result,
the ATF4 is produced. In the PERK signalling
pathway, ATF4 initiates the translation of two
critical downstream UPR target proteins, DNA
damage-inducible transcript (DDIT)3 and the
growth arrest and DNA damage-inducible protein
(GADD)34. GADD34 is vital in dephosphorylating
EIF2a and restores protein biosynthesis. Activated
GADD34 recruits the serine/threonine-protein
phosphatase 1 complex (PP1), which
dephosphorylates EIF2a and recovers protein
synthesis mediated by the PERK signalling
cascade. DDIT3 triggers apoptosis if the cell
undergoes persistent and unsolved ER stress.45
Thus, the PERK signalling pathway controls cell
fate under conditions of ER stress, although it
remains unclear how PERK regulates the balance
of both GADD34 and DDIT3 expression.
ATF6
ATF6 is the ER stress transducer that regulates the
third branch of the UPR signalling cascade. It is a
90 kDA protein with a transmembrane domain.46
Similar to PERK and IRE1, it is localised to the ER
membrane and constitutively bound and inhibited
by GRP78. In mammalian cells, there are two ATF6
isoforms, ATF6a and ATF6b.47 ATF6a, but not
ATF6b, is essential in the regulation of protein
folding and ERAD processes.47,48 In vivo, Atf6a-
deficient mice are more susceptible to ER stress
than wild-type mice, whereas Atf6b deficiency did
not affect in vivo responses to challenge with
tunicamycin that induces ERS stress,48,49 an
inhibitor of N-linked protein glycosylation that
robustly induces ER stress. ATF6 has distinct UPR
activation mechanisms that differ from those in
IRE1 and PERK. ATF6 is an ER-resident oligomer
under normal conditions. During ER stress, GRP78
detects and binds to misfolded proteins, and
simultaneously releases ATF6. ATF6 then
translocates to the Golgi apparatus, where its N-
terminal domain is cleaved by sphingosine-1-
phosphate and sphingosine-2-phosphate via
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intramembrane proteolysis.50 Cleaved ATF6 then
translocates to the nucleus where it binds to the
ER stress response element 1 and CAAT binding
protein. ATF6 thereby promotes target gene
expression and upregulates ER-resident protein
synthesis. It plays essential roles in maintaining ER
homeostasis, such as upregulating ER-resident
chaperones and initiating ER stress-dependent ER




Inflammasomes are signalling complexes51,52 that
can assemble in most innate immune cells,
including mast cells, basophils, neutrophils, and
macrophages.1 These are supramolecular, cytosolic
complexes containing the protease caspase-1, an
adaptor known as Apoptosis-associated Speck-like
protein containing Caspase Activation and
Recruitment Domain (CARD, ASC, CARD5,
PYCARD), and a sensor protein.53 Sensor protein
activation induces the recruitment and fibrillation
of ASC to form a large signalling platform called
the ASC speck or pyroptosome,4 and this complex
acts as a platform for proximity-induced activation
of caspase-1 protease function.54 Active caspase-1
then cleaves the inactive pro-interleukin (IL)-1b
and pro-IL-18 into active pro-inflammatory
cytokines IL-1b and IL-18. Inflammasome-driven IL-
1b and IL-18 production requires two signals. The
first signal can be either PAMPs, such as bacterial
lipopolysaccharides (LPS), or cytokines, such as IL-1
or tumour necrosis factor (TNF).55,56 During
pathogen challenge, PAMPs and cytokines trigger
downstream signalling cascades, for example via
nuclear factor kappa-light-chain-enhancer of
activated B cells (NF-kB).55,57 Primary functions of
this signal are to upregulate NLRP3 and pro-IL-1b
gene and protein expression .55 The second signal
activates the inflammasome, and can be provided
by DAMPs or microbial virulence factors, such as
Shigella sp. toxin and Staphylococcus aureus a-
haemolysin.55,57 This second signal activates
inflammasome sensor proteins, which then recruit
ASC and caspase-1 monomers to assemble the
inflammasome.1 Caspase-1 monomers dimerise on
the inflammasome to partially activate this
protease.54 Caspase-1 then self-cleaves in one
linker region to fully activate the protease and
induce substrate cleavage, after which it cleaves in
a second linker region to inactivate the
protease.54 Activated caspase-1 is a cysteine-
dependent protease that cleaves pro-IL-1b and
pro-IL-18 into functional IL-1b and IL-18 to initiate
the inflammatory responses.1 Active caspase-1 can
also trigger a form of cell death called pyroptosis,
by cleaving gasdermin D to generate an N-
terminal fragment that binds to the inner leaflet
of the plasma membrane to form 10–3-nm
diameter pores. Gasdermin D pores facilitate the
export of mature functional IL-1b and IL-18.58–60
As a consequence, cytosolic contents, including IL-
1b and IL-18, are released. Interestingly, microbial
NLRP3-activating signals, such as the bacterial
toxin nigericin, elicit a more potent and greater
inflammasome response compared to sterile
signals, such as ATP, reflecting the important
functions of the inflammasome in eliminating
pathogens and infection.56
Inflammasomes are categorised into three
groups: tripartite motif, AIM2-like receptors and
nucleotide-binding domain-like receptors (NLR)
based on their unique sensor protein that forms
the core for the assembly of inflammasome
complexes.61,62 The NLR family is distinguished by
its unique central nucleotide binding and
oligomerisation NACHT domain, which is usually
bookended by C-terminal leucine-rich repeats
(LRR) and an N-terminal CARD or Pyrin domain.63
Four distinct inflammasome sensors are
characterised within the NLR family: Nucleotide-
binding oligomerisation domain, LRR and Pyrin
domain containing (NLRP)3, NLRP1, NLRP6, and
Nucleotide-binding oligomerisation domain, LRR
and CARD containing (NLRC)4.55,57,61,63–65 We will
focus on the NLRP3 inflammasome that is most
widely implicated in ER stress and inflammatory
diseases.
NLRP3 inflammasome
The NLRP3 inflammasome has attracted much
attention as a therapeutic target, due to its
disease-inducing roles in many inflammatory
diseases, including arthropathy, COPD,
inflammatory bowel disease, multiple sclerosis,
Parkinson’s disease, diabetes, and severe
asthma.5,6,8–10,66,67 For instance, the essential role
of NLRP3 inflammasome is well presented in
multiple chronic inflammatory lung diseases, such
as asthma and COPD. Elevated NLRP3
inflammasome expression is reported in patients
with neutrophilic asthma,68 and drives the
pathogenesis of severe steroid-resistant
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experimental asthma.5 Similar events are also
observed in COPD models, and knockout of NLRP3
reduces the expression of inflammation markers
(IL-1 and IL-18).69
Like most other inflammasomes, NLRP3 contains
three major domains: a C-terminal LRR domain, a
central NACHT and an N-terminal Pyrin domain.53
NLRP3 activity requires ATP produced via the
ATPase function within the NACHT domain.70
Gain-of-function mutations in NLRP3 cause
cryopyrin-associated periodic syndromes (CAPS),
such as Muckle–Wells syndrome, familial cold
autoinflammatory syndrome and chronic infantile
neurologic cutaneous and articular syndrome.71
Conversely, loss-of-function NLRP3 variants are yet
to be discovered in humans, and are potentially
lethal. Bats, however, have suppressed
inflammasome responses enabling them to
tolerate many viruses such as coronaviruses
including SARS-CoV-2 that causes COVID-1972,73.
The NLRP3 inflammasome orchestrates cell
stress-induced inflammatory responses. NLRP3 is
activated by a myriad of stimuli, including
extracellular ATP that is released by damaged
host cells,74,75 and microbial molecules such as
RNA and bacterial toxins, that enable responses
to invading pathogens such as bacteria, viruses,
fungi, and parasites. Sha et al. showed that
human NLRP3 detects mRNA, tRNA, and
ribosomal RNA from both Gram-negative (e.g.
Escherichia coli, Pseudomonas aeruginosa,
Chromobacterium violaceum, Salmonella enterica
and Moraxella catarrhalis) and Gram-positive (e.g.
S. aureus, Listeria monocytogenes and
Enterococcus faecalis) bacteria.76 Intriguingly and
unlike human NLRP3, the murine NLRP3
inflammasome only responds to bacterial mRNA
but not to bacterial tRNA or rRNA.76 Animal
studies highlight the protective functions of the
NLRP3 inflammasome in host defence against
opportunistic fungi including Aspergillus
furmigatus, Saccharomyces cerevisiae, and
Candida albicans.77–81 Indeed, NLRP3
inflammasome signalling restricts fungal spread
in mice.82,83 Several studies also show that NLRP3
is also a sensor for viral infection. NLRP3
inflammasome signalling drives IL-1b production
in Ebola infection.84 However, some viruses, such
as Sendai virus and NS1 mutant influenza A virus,
inhibit IL-1b production by preventing NLRP3
assembly and detection of these viruses,
highlighting the limitations of NLRP3 in
combating such viral infections.85,86 However,
NLRP3 inflammasome activation does not always
play a protective role in infection. NLRP3
inflammasomes are deleterious late in influenza
A virus infections and NLRP3 knockout promotes
animal survival in some microbial infections.87–89
The mechanisms of activation of the NLRP3
inflammasome cascade remain to be fully
elucidated. Under physiological conditions, NLRP3
sensor molecules are thought to be in an auto-
inhibition state that renders them unable to
initiate signalling.90 Inflammasome licensing or
priming processes are required to induce NLRP3
into a signal-competent state ready for activation
by a second signal.91 During the priming process,
priming signals, including PAMPs, are recognised
by PRRs and acts as ligands that bind to toll-like
receptors (TLRs). These PAMPs include bacterial
lipopolysaccharide, lipoproteins, lipoteichoic acid,
peptidoglycans, 23S RNA, zymosan, mannan,
flagellin, viral double stranded RNA, small
interfering RNA, profilin, and viral DNA that are
enriched with unmethylated CpG-DNA motifs.92
Once attached to TLR, this interaction
subsequently activates the transcription factor NF-
kB, which then upregulates NLRP3 and pro-IL-1b
expression.93,94 This process is tightly regulated via
other cellular mechanisms including G-protein-
coupled receptor (GPCR) signalling and
microRNAs.95,96 In addition to regulating NLRP3
and pro-IL-1b expression, priming also induces
several post-translational modifications in
inflammasome components that facilitate
pathway activation by a second stimulus97,98
(Figure 1).
After priming, an activation signal such as
reactive oxygen species (ROS), lysosomal damage,
or damage to other membranes leading to
potassium efflux is required to initiate calcium
mobilisation and trigger NLRP3 activation.99–101
NLRP3 then undergoes oligomerisation and
attaches to the ASC adaptor protein via Pyrin-
Pyrin domain interactions.102,103 As a result, long
ASC filaments are generated through self-
association.102,103 Thereafter, inactive monomers
of caspase-1 bind to ASC through CARD-CARD
interactions.102,103 One study found that NLRP3
oligomerises before stimulation but this is
contrary to all others addressing this issue.104
Caspase-1 recruitment is essential for
inflammasome activation and allows for caspase-1
proximity-induced dimerisation and self-cleavage
reactions that convert inactive caspase-1
monomers into active protease dimers.54
2021 | Vol. 10 | e1247
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Several non-exclusive models are proposed for
NLRP3 inflammasome activation. The most
common posits that NLRP3 is a sensor for
perturbations in cytosolic ion balance. According
to this model, NLRP3-activating ionophores and
microbial pore-forming toxins (e.g. nigericin,
valinomycin, gramicidin, perfringolysin-O and
streptolysin-O) induce potassium efflux and
calcium mobilisation in the cell, which serves as an
activation signal for NLRP3.105,106 Chloride
channel-mediated chloride efflux is proposed as
an alternative pathway to activate NLRP3.107,108
Inhibition of chloride efflux through volume-
regulated anion channels using fenamate
suppresses NLRP3 activation.7
Emerging literature suggests that mitochondria
also play important roles in activating NLRP3.
Studies indicate that mitochondria facilitate the
assembly of the NLRP3 inflammasome,109–111 such
as via the resident mitochondrial anti-viral
signalling adaptor protein (MAVS). Subramanian
et al.109 reported that MAVS deficiency selectively
suppressed macrophage NLRP3 responses to ATP
and nigericin but did not affect NLRP3 responses
to crystalline compounds such as silica and alum.
NLRP3 can also be activated by mitochondrial-
derived molecules, such as ROS and mitochondrial
DNA.110,111
Since NLRP3 signalling is critical in many
inflammasome-related disorders, inhibitors offer
high therapeutic potential for suppressing NLRP3-
induced inflammation. A specific and potent
NLRP3 inhibitor (MCC950) was recently developed
for the treatment of inflammasome-mediated
diseases including CAPS and other complex
disorders like type 2 diabetes and
atherosclerosis.112,113 A strong body of evidence
also suggests that MCC950 effectively suppresses
Figure 1. NLRP3 inflammasome signalling cascade. This cascade is separated into three stages, which are transcriptional priming, post-
translational modification, and activation. During the transcriptional priming stage, PAMPs or DAMPs bind to TLR or TNF induce the first signal,
which subsequently initiates the NF-ᴋB/MAPK signalling pathway that upregulates NLRP3, pro-IL-1b and pro-IL-18. In parallel, the first signal also
triggers JNK-mediated ASC phosphorylation and LUBAC-mediated NLRP3 ubiquitination, which are essential for post-translational modification of
the NLRP3 receptor. The third activation stage is initiated when there is K+ efflux, mitochondrial stress or lysosomal damage occurs in the
cytoplasm. These events generate another signal that activates the primed NLRP3 receptor, which then initiates NLRP3 inflammasome complex
assembly. The inflammasome complex then promotes the conversion of inactive caspase-1 to active caspase-1, which then cleaves pro-IL-1b and
pro-IL-18 into active IL-1b and IL-18. Both IL-1b and IL-18 then initiate inflammation. ASC, Apoptosis-associated Speck-like protein containing a
CARD; DAMP, Danger-Associated Molecular Pattern; IL-1b, Interleukin 1b; IL-18, Interleukin 18; JNK, c-Jun N-terminal kinase; K+, Potassium Ion;
LUBAC, Linear Ubiquitin Assembly Complex; MAPK, Mitogen-Activated Protein Kinase; NF-kB, Nuclear Factor Kappa-light-chain-enhancer of
activated B cell; NLRP3, NLR family pyrin domain containing 3; PAMP, Pathogen-Associated Molecular Pattern; ROS, Reactive Oxygen Species;
TLR, Toll-Like Receptor; TNF, Tumor Necrosis Factor; TNFR, TNF Receptor.
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cardiovascular disease,114 Alzheimer’s,115 non-
alcoholic fatty liver disease,116 Chikungunya,117
multiple sclerosis118 and severe steroid-resistant
asthma.5 Interestingly, interferon (IFN) and the
nitric oxide synthase-2-mediated NO pathways
were shown to inhibit NLRP3 activation and
thereby prevent tuberculosis-associated
pathology.119 Mao et al.120 showed that a similar
NO-dependent mechanism suppresses NLRP3
activation during LPS challenge to protect against
septic shock. Several NLRP3 inhibitors, such as
IZD334 and IZD174 are currently in human clinical
trials, including clinical trials NCT04086602,
NCT04338997 and NCT04015076.121–123
ER STRESS, INFLAMMASOMES AND
INFLAMMATION
Like inflammasomes, but to a lesser extent, ER
stress has been linked to the induction of
inflammation, and also now to inflammasome-
induced inflammation (Figure 2).
ER stress and inflammation
Several links between ER stress/UPR and
inflammation have been proposed.13,124 Such links
are well demonstrated in genetic- and
pharmacologically induced hepatic steatosis
in vivo models.125 In these models, ER stress
induced by tunicamycin challenge in mice caused
significant caspase-1-dependent upregulation of
UPR (DDIT3, GRP78, and IRE1a) and inflammation
(IL-1b) marker expression .125,126 Tunicamycin-
induced hepatic inflammation was suppressed,
and steatosis and ER stress-induced hepatocyte
cell death and pyroptosis was ameliorated by
deletion of caspase-1.125 Guthrie et al.127 used an
ER stress-challenge astrocyte model to show that
inhibiting PERK could reduce the expression of
Figure 2. Complex interplay of ER stress and NLRP3 inflammasomes in inflammation. ER stress- and NLRP3 inflammasome-induced inflammation
demonstrate strong inter-relationships. They are linked via cell stressors such as mitochondrial stress, cytokines, RIP1 and Angiotensin II. Infectious
agents, such as SARS-CoV, also induce ER stress/NLRP3 inflammasome-induced inflammation via its RNA’s open reading frame, ORF8b. ATF4,
Activating transcription factor 4; ATF6, Activating Transcription Factor 6; DDIT3, DNA Damage-Inducible Transcript 3; EIF2a, Eukaryotic Initiation
Factor 2a; GRP78, Glucose-Regulated Protein 78; IL-1b, Interleukin 1b; IL-6, Interleukin 6; IL-8, Interleukin 8; IL-18, Interleukin 18; IRE1, Inositol-
Requiring Enzyme 1; NF-kB, Nuclear Factor Kappa-light-chain-enhancer of activated B cell; NLRP3, NLR family pyrin domain containing 3; PERK,
PKR-like ER kinase; pEIF2a, Phosphorylated EIF2a; ORF8b, Open Reading Frame 8b; RIP1, Receptor-Interacting serine/threonine-Protein kinase 1;
ROS, Reactive Oxygen Species; sXBP1, spliced XBP1; TNF, Tumor Necrosis Factor; UPR, Unfolded Protein Response; XBP1, X-box Binding Protein 1.
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inflammatory cytokines (e.g. IL-6) and chemokines
(e.g. C-C motif chemokine ligand [CCL]2, and
CCL20) to suppress inflammation. While complete
inhibition of PERK can induce apoptosis and
haplo-insufficiency, its partial inhibition relieved
ER stress-induced inflammation without impinging
on UPR-dependent pro-survival responses showing
that these processes are not completely
dependent.127 Collectively, these studies show
essential roles for ER stress/UPR during
inflammation.
ER stress, inflammasomes and inflammation
Notably, while NLRP3 inflammasome is known to
have essential roles, the pathogenic functions of
UPR in chronic inflammatory diseases such as
those in the lung are also becoming increasingly
clear.13,128–130 Caspase-1 and IL-1b and involved.
Thus, it is likely that ongoing chronic ER stress/
UPR induces inflammasome activation to drive
inflammation in chronic lung and other diseases;
however, the mechanisms that underpin these
links remain to be elucidated. Many studies have
identified roles for ER stress or NLRP3
inflammasome in inflammation pathway, some
studies now link ER stress with NLRP3
inflammasome activity and inflammation. Several
non-alcoholic fatty liver diseases, ranging from
simple steatosis to non-alcoholic steatohepatitis
that can lead to hepatocellular carcinoma.131
Here, there are associations between increased
circulating LPS in patients with steatohepatitis
that is thought to lead to the induction of ER
stress/UPR and consequently NLRP3 inflammasome
activation and hepatocyte death.132 Showing
cause and effect, challenge of obese mice with
LPS or tunicamycin triggers IRE1a and PERK
signalling cascades, leading to DDIT3
overexpression, NLRP3 inflammasome activation
and hepatocyte death.131,132 Furthermore,
hepatocytes could be rescued from LPS-induced
cell death by treatment with TUDCA, an
ambiphilic bile acid capable of relieving ER stress,
indicating the therapeutic potential of ER stress
inhibitors.132 Similar links between ER stress,
inflammation and NLRP3 inflammasome pathways
are also observed in driving chronic pancreatitis.
Cerulein-induced acute and chronic pancreatitis in
mice is underpinned by increased UPR and NLRP3
inflammasome activation and pro-inflammatory
responses.133 Moreover, treatment with withaferin
A, a small molecule inhibitor of NF-jB activity,
significantly attenuated all of these cerulein-
induced processes, suggesting a close relationship
between ER stress-induced inflammasome
activation and inflammation in acute and chronic
pancreatitis.133 Collectively, these findings provide
strong evidence for the involvement of both ER
stress and NLRP3 inflammasome in different
disorders.
Although studies have demonstrated the
presence of both ER stress and NLRP3
inflammasome in different inflammatory
disorders, the mechanism by which ER stress
triggers NLRP3 inflammasome function and
inflammation is unclear. So far, there are no
studies that have directly interrogated the effects
of ER stress markers (GRP78, IRE1a, PERK or
ATF6a) in the NLRP3 inflammasome signalling
cascade. Some studies report that ER stress can
alone initiate NF-kB-dependent inflammation
in vitro and in vivo, to promote NLRP3 and IL-1b
expression and contribute to inflammasome
priming.134 Bronner et al.135 showed that ER stress
activates NLRP3, through a mechanism requiring
caspase-2-related mitochondrial dysfunction and
ROS. Menu et al. showed that ER stress activates
NLRP3 inflammasomes independently of a classical
UPR, through a mechanism involving ER–
mitochondrial interactions.136 Specifically, they
showed that knock down of UPR effectors, PERK,
IRE1a and ATF6a did not affect ER stress-induced
inflammasome activation, which instead required
ROS generation and potassium efflux.136
Other studies have suggested that some factors
act as essential regulators of both ER stress and
NLRP3 inflammasomes during inflammatory
responses. One of them is receptor-interacting
serine/threonine-protein kinase 1 (RIP1), which
was reported to critically regulate ER stress-
induced NLRP3 inflammasome activation.137 Here,
ER stress-induced RIP1 phosphorylation, and
pharmacological inhibitors of RIP1 activity
reduced ER stress-induced caspase-1 cleavage and
IL-1b secretion in macrophages.137 Also,
downstream effectors of RIP1, ROS and
mitochondria fission factor dynamin-related
protein (DRP)1 activate NLRP3 inflammasomes.137
Angiotensin II administration to human kidney
proximal epithelial cells elevated the expression of
both UPR (GRP78, phosphorylated EIF2a) and
NLRP3 inflammasome signalling (NLRP3, ASC,
caspase-1, IL-1b, IL-18) markers that could be
suppressed by the angiotensin II antagonist,
telmisartan.138 Collectively these findings suggest
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that some factors may potentially link ER stress
with NLRP3 inflammasome activity.
Interestingly, microbial infection may also
induce ER stress and NLRP3 inflammasome
activation. During Mycobacterium bovis,
Mycobacterium tuberculosis, and Treponema
pallidum infection ER stress triggered
macrophages to produce mature IL-1b via the
NLRP3 inflammasome cascade.139–141 Similar
events were also observed in severe acute
respiratory syndrome (SARS) – coronavirus (SARS-
CoV) infection.142 In that study, a SARS-CoV
accessory protein, open reading frame 8b
(ORF8b), was shown to interact with NLRP3 and
induce inflammasome signalling.142 Accumulation
of ORF8b can also induce ER stress, and
subsequently cause autophagy and lysosomal
damage via transcription factor EB.142 SARS-CoV
viroporin 3a also activates the NLRP3
inflammasome to trigger the production of IL-1b
production in LPS-primed macrophages.143 It is
currently unclear whether SARS-CoV-2, the
causative agent of COVID-19, is similarly able to
directly activate the NLRP3 inflammasome, but
this seems likely, given their genetic similarity and
conserved ORF8b and viroporin 3a
proteins.73,144,145 Indeed, patients with severe
COVID-19 show evidence of an excessive
inflammatory response, including increased
circulating inflammatory cytokines such as IL-1b,
IL-2, IL-6, IL-7, IFN-c, IP-10 and TNF.73,146,147 These
patients also experience significant lung
inflammation and acute lung injury, often
resulting in acute respiratory distress syndrome
(ARDS) and the need for mechanical
ventilation.73,148,149 Importantly, NLRP3
inflammasome signalling drives acute lung injury
and ARDS, suggesting that NLRP3 may be
responsible for lung damage in severe COVID-
19.150 Nevertheless, further studies are required to
understand whether and how such ER stress-
induced inflammasome activation pathways are
initiated by specific types of microbial infections.
THERAPEUTIC STRATEGIES TO
AMELIORATE ER STRESS AND
INFLAMMASOME-INDUCED
INFLAMMATION
Various phytochemicals extracted from traditional
medicinal plants as are increasingly being pursued
as potential therapies for treating inflammation
induced by ER stress and the inflammasome. For
example, Momordica charantia, which also known
as bitter melon, is traditionally used as medicine in
relieve colitis, which strongly linked with ER stress
and inflammation.14,151 Puerarin, an active
compound of Kudzu root, which is a widely used
functional food in treating ARMD in China, was
reported to relieve ER stress and the exacerbation
of NLRP3-activated inflammation.49 It suppressed
amyloid b-induced ER stress, lipid peroxidation,
and NLRP3 inflammasome activation in LPS-primed
ARPE cells in a dose-dependent manner. The anti-
inflammatory effects were exerted by activating
the nuclear factor (erythroid-derived 2) like (NRF)2
antioxidant pathway, as well as attenuating IRE1
and PERK phosphorylation and ATF6 nuclear
expression. Mangiferin, a natural polyphenol with
a C-glycoxylxanthone structure from mangos
(Mangifera indica), also possesses potential
therapeutic benefit for treating ER stress and
inflammasome-induced disease. Mangiferin
inhibited ER stress in saturated fatty acid
palmitate-challenged mice, and suppressed the
expression of NLRP3, caspase-1 and IL-1b.152 A
phytochemical gastrodin was isolated from a
native herb (Gastrodia elata) that is widely used
for treating pain-relief and may have therapeutic
potential for suppressing ER stress and NLRP3
inflammasome activity.153 Gastrodin administration
in mice with streptozodin-induced diabetes
mellitus significantly reduced the expression of ER
stress markers (e.g. PERK, GRP78, DDIT3) and
NLRP3 inflammasome pathway components (e.g.
NLRP3, ASC, IL-1b).153 Collectively, the data
suggest that phytochemicals may hold therapeutic
potential for ameliorating inflammation induced
by ER stress and the NLRP3 inflammasome.
Interestingly, several endogenous factors in
humans may offer therapeutic potential for
ameliorating ER stress and inflammasome-induced
inflammation. b-hydroxybutyrate is a ketone body
produced by the liver, that is utilised by the brain,
muscle, and heart as an energy source under
hypoglycaemic conditions.154 b-hydroxybutyrate
suppressed both and ER stress (IRE1, PERK, ATF6)
and inflammasome activity in vitro (HEPG2 human
hepatoma cell line) and in vivo (Sprague Dawley
rats).154 Ghrelin is another endogenous factor
proposed to be a potential inhibitor of ER stress-
dependent NLRP3 inflammasome-induced
inflammation.155 It is a brain protein that binds to
the growth hormone secretagogue receptor and
upregulates growth hormone production; hence,
it plays essential roles in cell growth and
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development.155 Ghrelin induction reduced the
expression of ER stress components, including
DDIT3, ATF4, IRE1a, GRP78, PERK and
phosphorylated EIF2a, and of NLRP3
inflammasome-induced inflammatory responses,
such as caspase-1, NLRP3, IL-1b and IL-18 in
unilateral ureteral obstruction-induced renal
fibrosis mouse models.155 Collectively, these results
provide evidence that ghrelin is a potential
therapy in treating ER stress- and NLRP3-
inflammasome-related inflammation.
The artificial chemical chaperone 4PBA was also
shown to suppress ER stress and NLRP3
inflammasome-induced inflammation. It interacts
with the hydrophobic domain of misfolded
proteins to prevent their aggregation and thereby
suppress ER stress.156 Wang et al.138 revealed that
cells pre-treated with 4PBA exhibited significantly
reduced expression of inflammasome markers,
including NLRP3, ASC, caspase-1, IL-1b and IL-18,
during angiotensin II-induced inflammation. Thus,
4PBA could also be a viable therapeutic option for
ER stress and inflammasome-induced
inflammation.
CONCLUSIONS
ER stress has a strong causative relationship with
inflammasome-mediated inflammation. There is
growing evidence for the significant roles of ER
stress and inflammasomes in the pathogenesis of
inflammatory diseases. Targeting ER stress or the
NLRP3 inflammasome may pave the way for the
development of novel and effective therapies for
inflammatory diseases, as well as enhancing the
efficacy of current agents for improved disease
management.
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